P635: Enteral nutrition in the treatment of young adults with active Crohn's diseaseECCO '17 Barcelona
2017
P636: Reproducibility of the main prognostic factors for postoperative recurrence in a cohort of patients with Crohn's disease under anti-Tnf therapyECCO '17 Barcelona
2017
P637: Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical responseECCO '17 Barcelona
2017
P638: Release of 5-aminosalicylic acid from mesalazine formulations: a novel dynamic dissolution model simulating gastrointestinal pH changesECCO '17 Barcelona
2017
P639: Switching from originator-infliximab to biosimilar-Infliximab in IBD-patients does not lead to significant changes in infliximab trough levelsECCO '17 Barcelona
2017
P640: Serum ustekinumab levels achieved with a subcutaneous induction regimen correlate to clinical outcome – a prospective studyECCO '17 Barcelona
2017
P641: Long-term outcome of adalimumab therapy and predictors of response in 254 patients with Crohn's disease: a hospital-based cohort study from KoreaECCO '17 Barcelona
2017
P642: Impact of histological and endoscopic remission in clinical recurrence and recurrence-free time in ulcerative colitisECCO '17 Barcelona
2017
P643: Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel diseaseECCO '17 Barcelona
2017
P644: Factors and salvage surgery for treatment of pouch failure after restorative proctocolectomy for ulcerative colitis – a single-institution studyECCO '17 Barcelona
2017
P645: The introduction of infliximab therapeutic drug level monitoring for is associated with cost savings in a cohort of patients in a large district general hospitalECCO '17 Barcelona
2017
P646: Low FODMAPs diet as a magic bullet in reducing symptoms in different gastrointestinal diseasesECCO '17 Barcelona
2017
P647: Tuberculosis in patients treated with vedolizumab: clinical trial and post-marketing case seriesECCO '17 Barcelona
2017
P648: The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBDECCO '17 Barcelona
2017
P649: Does switching to low dose thiopurine and allopurinol prevent IBD patients with evidence of hypermethylation on standard dose thiopurines from developing hepatotoxicity and drug side effects?ECCO '17 Barcelona
2017
P650: The prognostic impact of radical resection margins on the Recurrence of Crohn's diseaseECCO '17 Barcelona
2017
P651: Barriers to clinical research in children with inflammatory bowel disease: the patients' perspectiveECCO '17 Barcelona
2017
P652: Unmet needs of physicians managing inflammatory bowel disease. A Survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)ECCO '17 Barcelona
2017
P653: The efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysisECCO '17 Barcelona
2017